Study Ranks Gene Targets for More Effective, Tailored Cancer Therapies

Study Ranks Gene Targets for More Effective, Tailored Cancer Therapies
A large-scale screening provided a system to prioritize gene targets for the potential development of tailored cancer therapies. According to the scientists, the findings may also help produce the Cancer Dependency Map, a comprehensive rulebook for the precision treatment of cancer. The study, “Prioritisation of cancer therapeutic targets using CRISPR-Cas9 screens,” was published in the journal Nature. Tailored therapies are more effective and safer than surgery, chemotherapy, and radiotherapy, but limited knowledge of target candidates has limited their use to a small subset of cancer patients. Strategies to identify and prioritize targets would thereby boost their success and help develop new treatments. The CRISPR-Cas9 gene editing approach is able to deplete genes from the genome with high specificity, allowing researchers to study their function with great accuracy. Thus, a team at the Wellcome Sanger Institute and Open Targets — a collaboration among the Wellcome Sanger Institute, EMBL-EBI, GSK, BiogenTakeda, and Celgene — conducted a large CRISPR-Cas9 screen to find key genes for cancer survival and likely treatment targets. “CRISPR is an incredibly powerful tool that enables us to do science at a scale and with a precision that we couldn't do five years ago
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *